These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35116349)

  • 1. Tumor-associated eosinophilia in a patient with
    Geng N; Hu W; Ge H; Xie S; Ding C
    Transl Cancer Res; 2021 Nov; 10(11):4988-4996. PubMed ID: 35116349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon
    Ou L; Tang Y; Deng Y; Guo L; He Q; He T; Feng W
    Front Oncol; 2022; 12():911362. PubMed ID: 35957915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful crizotinib monotherapy in
    Yoshimura K; Inui N; Karayama M; Inoue Y; Enomoto N; Fujisawa T; Nakamura Y; Takeuchi K; Sugimura H; Suda T
    Respir Med Case Rep; 2017; 20():160-163. PubMed ID: 28271038
    [No Abstract]   [Full Text] [Related]  

  • 4. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
    Long Y; Zhang K; Li Y; Yu M; Zhu J; Huang M
    Ann Palliat Med; 2020 Sep; 9(5):3609-3613. PubMed ID: 32648452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with Anlotinib After Chemotherapy and EGFR-TKI Resistance in Lung Adenosquamous Carcinoma with Concurrent
    Wu Y; Zhang K; Guan J; Wu W; Zhang J; Chen H
    Cancer Manag Res; 2021; 13():7047-7053. PubMed ID: 34526820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.
    Jin LL; Wu ZZ; Wang YL; Chen DS; Li S; Xiao M; Zhao X
    Invest New Drugs; 2021 Oct; 39(5):1419-1421. PubMed ID: 33835358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Adenocarcinoma with Paraneoplastic Hyper-Eosinophilia Not Responding To Pembrolizumab.
    Wehbe H; Kozah M; Koubaissi SA
    Clin Med Insights Circ Respir Pulm Med; 2021; 15():11795484211030164. PubMed ID: 34377046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
    Wang Y; Tian P; Xia L; Li L; Han R; Zhu M; Lizaso A; Qin T; Li M; Yu B; Mao X; Han-Zhang H; He Y
    Lung Cancer; 2020 Aug; 146():165-173. PubMed ID: 32540560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline
    Jiao Y; Fang C; Yang Y; Shao L; Huang Y; Sun Q; Dong Y
    Onco Targets Ther; 2021; 14():2417-2421. PubMed ID: 33854337
    [No Abstract]   [Full Text] [Related]  

  • 11. Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation.
    Zhu Y; Tang J; Li X; Qin T; Wei Y
    Onco Targets Ther; 2020; 13():10447-10451. PubMed ID: 33116624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic
    Cai B; Li X; Huang X; Ma T; Qu B; Yu W; Yang W; Zhang P; Chen J; Liu F
    Front Oncol; 2021; 11():738832. PubMed ID: 34926253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
    Yamamoto Y; Kodama K; Maniwa T; Takeda M
    J Cardiothorac Surg; 2017 Nov; 12(1):98. PubMed ID: 29169381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
    J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.
    Gu ZB; Liao LM; Yao GJ; Fang M; Huang L
    Curr Probl Cancer; 2021 Oct; 45(5):100702. PubMed ID: 33454089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-line treatment with tyrosine kinase inhibitors enabled in 4-year survival for patient with stage IV lung adenocarcinoma: a case report.
    Yin Y; Qin J
    Ann Palliat Med; 2021 Jun; 10(6):6990-6996. PubMed ID: 33183014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.